Cancer as a cause of death among people with AIDS in the United States.
BACKGROUND
People with human immunodeficiency virus (HIV) infection and AIDS have an elevated risk for cancer. Highly active antiretroviral therapy (HAART), which has been widely available since 1996, has resulted in dramatic decreases in AIDS-related deaths.


METHODS
We evaluated cancer as a cause of death in a US registry-based cohort of 83,282 people with AIDS (1980-2006). Causes of death due to AIDS-defining cancers (ADCs) and non-ADCs (NADCs) were assessed. We evaluated mortality rates and the fraction of deaths due to cancer. Poisson regression assessed rates according to calendar year of AIDS onset.


RESULTS
Overall mortality decreased from 302 deaths per 1000 person-years in 1980-1989, to 140 deaths per 1000 person-years in 1990-1995, and to 29 deaths per 1000 person-years in 1996-2006. ADC-related mortality decreased from 2.95 deaths per 1000 person-years in 1980-1989 to 0.65 deaths per 1000 person-years in 1996-2006 (P < .01), but the fraction of ADC-related deaths increased from 1.05% to 2.47% in association with decreases in other AIDS-related deaths. Non-Hodgkin lymphoma was the most common cancer-related cause of death (36% of deaths during 1996-2006). Likewise, NADC-related mortality decreased from 2.21 to 0.84 deaths per 1000 person-years from the period 1980-1989 to the period 1996-2006 (P < .05), but the fraction of NADC-deaths increased to 3.16% during 1996-2006. Lung cancer was the most common NADC cause of death (21% of cancer-related deaths in 1996-2006).


CONCLUSIONS
Cancer-related mortality decreased in the HAART era, but because of decreasing mortality due to AIDS, cancers account for a growing fraction of deaths. Improved cancer prevention and treatment, particularly for non-Hodgkin lymphoma and lung cancer, would reduce mortality among people with AIDS.
Simard
Edgar P
EP
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20892, USA.
Engels
Eric A
EA
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000188:drug therapy; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000706:statistics & numerical data; D002423:Cause of Death / Q000639:trends; D015331:Cohort Studies; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology* / Q000401:mortality*; D014481:United States / Q000453:epidemiology
D019380:Anti-HIV Agents
AIDS. 2009 Sep 24;23(15):2029-37
19531926
Leuk Lymphoma. 2006 Sep;47(9):1822-9
17064995
J Acquir Immune Defic Syndr. 2003 Jan 1;32(1):62-9
12514415
Blood. 2010 Apr 15;115(15):2986-7
20395421
IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492
9705682
Br J Haematol. 2007 Mar;136(5):685-98
17229246
AIDS. 2009 May 15;23(8):875-85
19349851
J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):378-87
11917243
Blood. 2010 Apr 15;115(15):3017-24
20130244
Gastroenterology. 2007 Jun;132(7):2557-76
17570226
Ann Intern Med. 2006 Sep 19;145(6):397-406
16983127
Int J Cancer. 2008 Jul 1;123(1):187-94
18435450
Clin Infect Dis. 2005 Feb 1;40(3):490-1
15668878
JAMA. 1999 Jun 23-30;281(24):2305-15
10386555
Blood. 2010 Apr 15;115(15):3008-16
20023215
Clin Infect Dis. 2010 May 15;50(10):1387-96
20380565
AIDS. 2006 Aug 1;20(12):1645-54
16868446
MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19
1361652
N Engl J Med. 1998 Mar 26;338(13):853-60
9516219
Am J Public Health. 1995 Nov;85(11):1552-5
7485671
J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):293-9
15980688
J Acquir Immune Defic Syndr. 2006 Sep;43(1):47-55
16936558
Clin Infect Dis. 2009 Mar 1;48(5):633-9
19202627
Lancet. 1998 Jun 20;351(9119):1833-9
9652666
J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):194-200
16394852
J Clin Oncol. 2006 Mar 20;24(9):1383-8
16549832
MMWR Morb Mortal Wkly Rep. 2008 Jun 13;57(23):631-4
18551099
J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34
16878047